Therapeutical Potential of Lamotrigine in the Therapy of Childhood Epilepsy. A Review

Czech version

Authors: H. Ošlejšková
Authors‘ workplace: LF MU a FN Brno ; Klinika dětské neurologie, Centrum pro epilepsie, Dětská nemocnice
Published in: Cesk Slov Neurol N 2007; 70/103(5): 495-504
Category: Review Article

Overview

Lamotrigine (LTG) has been applied as a broad-spectrum AE in children above 2 years of age since 2002. It is indicated for add-on therapy of epilepsies with partial and generalized seizures, including tonic-clonic seizures and seizures associated with Lennox-Gastaut’s syndrome (LGS). After managing seizures by means of a combined therapy, simultaneous application of other antiepileptic drugs (AEDs) may be terminated and LTG monotherapy continues. Since 2005 LTG has been also indicated as monotherapy for typical absence seizures. In children and adolescents over 12 years of age, the indication spectrum is the same as that in adults. Childhood epilepsy, if compared with adult age, has got a number of specific features – distinct metabolism of AEs, different spectrum of seizures, incidence of epileptic syndromes linked to age and development, more types of seizures within one epilepsy, and potentially negative influence of non-compensated seizures and adverse effects (AE) of AEs on cognitive profile, behavior and development of a young patient. The report has given evidence of LTG effects on seizures and its acceptable tolerability in childhood. There are mentioned methods of how to avoid the most serious AE and unfavourable drug interactions. It does not substitute a Summary of information about the preparation (SIP).

Key words:
lamotrigine – epilepsy – seizure – cognition – behavior – adverse effects – worsening of seizures

Sources

1. Cowan LD, Bodensteiner JB, Leviton A, Doherty L. Prevalence of the epilepsies in children and adolescents. Epilepsia 1989; 30: 94-106.

2. Eriksson KJ, Koivikko MJ. Prevalence, Classification, and Severity of Epilepsy and Epileptic Syndromes in Children. Epilepsia 1997; 38(12): 1275-82.

3. Waaler PE, Blom BH, Skeidsvoll H, Mykletun A. Prevalence, Classification, and Severity of Epilepsy in Children in Western Norway. Epilepsia 2000; 41(7): 802-810.

4. Hauser WA. Seizure disorders: the changes with age [review]. Epilepsia 1992; 33(Suppl 4): S6-14.

5. Sillanpää M. Children with epilepsy as adults: outcome after 30 years of follow-up. Acta Pediatr Scand 1990; Suppl 368: 1-78.

6. Sillanpää M. Long-term autcome of epilepsy. Epileptic Disord 2000; 2: 79-88.

7. Chevrie JJ, Aicardi J. Convulsive disorders in the first year of life: neurologic and mental autcome and mortality. Epilepsia 1978; 19: 67-74.

8. Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol 2002 Jan; 17(Suppl 1): S4-17.

9. Pugh CB, Garnett WR. Current issues in the treatment of epilepsy. Clinical Pharmacy 1991; 10: 335-58.

10. Arts WF, Brouwer OF, Peters AC, Stroink H, Peeters EA, Schmitz PI et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain 2004; 127: 1774-1784.

11. Guerrini R, Belmonte A, Strumia S, Hirsch E. Exacerbation of epileptic negative myoclonus by carbamazepine or phenobarbital in children with atypical benign rolandic epilepsy. Epilepsia 1995; 36(Suppl 3): S65.

12. Parmeggiani L, Seri S, Bonanni P, Guerrini R. Electrophysiological characterization of spontaneus and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neuropharmacol 2004 Jan; 115(1): 50-58.

13. Elger C, Bauer J, Scherrmann J, Widman G. Aggravation of focal epilepsies by antiepileptic drugs. Epilepsia 1998; Suppl 3: S15-S18.

14. O´Donaghue MF, Sander JW. The mortality associated with epilepsy with particular reference to sudden unexpected death: a review. Epilepsia 1997; 38: 31-46.

15. Leach MJ, Randall AD, Stefani A et al. Lamotrigin: mechanism of action. In: Levy RH, Mattson RH, Meldrum BS et al (Eds). Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins 2002: 363-369.

16. Leach MJ et al. Lamotrigine: mechanisms of action. In: Levy RH et al (Eds). Antiepileptic drugs. 4th ed. New York: Raven Press 1995: 861-869.

17. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999; 53: 1724-1731.

18. Duchowny M, Kustra RP, Warnock B et al. Onset of action of lamotrigine in children with partial seizures. Poster presented at the Annual Meeting of the Child Neurology Society, Ottawa, Canada, October 13-16, 2004.

19. Parmeggiani L, Belmonte A, Ferrari AR et al. Add-on lamotrigine treatment in children and young adults with sever partial epilepsy: an open, prospective, long-term study. J Child Neurol 2000; 15: 671-674.

20. Bitton V, Sackellares JC, Vuong A et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65: 1737-1743.

21. Trevathan E, Kerls SP, Hammer AE et al. Double-blind, placebo-controlled evaluation of lamotrigine adjunctive therapy in children and adolescents with primary generalized tonic-clonic seizures. Poster presented at the 57th Annual Meeting of the American Academy of Neurology, Miami Brach, FL, April 9-16, 2005.

22. Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA. Lamotrigine Adjunctive Therapy Among Children and Adolescents With Primary Generalized Tonic-Clonic Seizures. Pediatrics 2006; 118; 371-378.

23. Frank LM, Enlow T, Holmes GL et al. Lamictal (lamotrigin) monotherapy for typical absence seizures in children. Epilepsia 1999; 40: 973-979.

24. Morris GL, Hammer AE, Kustra RP et al. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004; 5(4): 509-512.

25. Timmings PL, Richens A. Efficacy of lamotrigine as monotherapy for juvenile myoclonic epilepsy: pilot study results. Epilepsia 1993; 34(Suppl 2): S160.

26. Sharpe C, Buchanan N. Juvenile myoclonic epilepsy: diagnosis, management and outcome. Med J Aust 1995; 162: 133-134.

27. Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994; 344: 1375-1376.

28. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 1993; 24: 339-340.

29. Schimschock JR, Hammer AE, Kustra RP et al. Effects of lamotrigine monotherapy in patients with newly diagnosed juvenile myoclonic epilepsy: An open-label study. Curr Ther Res 2005; 66(3):230-237.

30. Eriksson AS, Nergårdh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998; 39: 495-501.

31. Motte J, Trevathan E, Arvidsson JFV et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997; 337:1807-1812.

32. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (The Lennox Gastaut Syndrome). Epilepsia 1997; 38: 68-73.

33. Dulac O, Kaminska A. Use of Lamotrigine in Lennox-Gastaut and Related Epilepsy Syndromes. J Child Neurol 1997; 12(Suppl 1): S23-28.

34. Besag FMS, Wallace SJ, Dulac O et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991-997.

35. Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 3: 51-56.

36. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-367.

37. Uvebrant P, Bauziene R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994; 25: 284-289.

38. Steinhoff BJ, Ueberall MA, Siemes H et al. The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Seizure 2005; 14: 597-605.

39. Pressler R, Robinson RO, Wilson GA, Binnie CD. Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy. J Pediatr 2005; 146: 112-117.

40. Franz DN, Tudor C, Leonard J et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia 2001; 42(7): 935-940.

41. Coppola G, Pascotto A. Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. Brain Dev 1997; 19: 398-402.

42. Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995; 4: 233-236.

43. Messenheimer JA, Giorgi L, Risner M et al. The Tolerability of lamotrigine in children. Drug Saf 2000; 22: 303-312.

44. Messenheimer JA. Rash in adult and pediatric patients treted with lamotrigin. Can J Neurol Sci 1998; 25: S14-S18.

45. Dooley J, Camfield P, Gordon K et al. Lamotrigin – induced rash in children. Neurology 1996; 38: 68-73.

46. Levy RH, Mattson RH, Meldrum BS, Perucca E. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.

47. Morselli PL, Pippenger CE, Penrg JK. Antiepileptic drug therapy in pediatrics. New York: Raven Press Leach 1983.

48. Pina-Garza JE, Womble G, Blum D et al. Safety and efficacy of lamotrigine in infants age 1-24 months with partial seizures – interim open-label results. Poster presentation at the annual meeting of the American Epilepsy Society, Seattle, WA. December 6-12, 2002.

49. May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996; 18(5): 523-531.

50. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39(5): 508-512.

51. Crespel A, Genton P, Berramdane M, Coubes P, Monicard C, Baldy-Moulinier M, Gelisse P. Lamotrigine associated with exacerbation or de novo myoclonus in idiopatic generalized epilepsies. Neurology 2005 65(5): 762-764.

52. Biraben A, Allain H, Scarabin JM, Schück, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigin. Neurology 2000; 55(11): 1758.

53. Cerminara C, Montanaro ML, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology 2004; 63(2): 373-375.

54. Ošlejšková H. Zhoršování epileptických záchvatů a epilepsií antiepileptiky – je to možné? Česk Slov Neurol N 2007; 70/103(2): 137–142.